Allarity Therapeutics (ALLR) Expects Q4 EPS of $0.01–$0.04

Allarity Therapeutics (ALLR) reported $24.1M in cash at Q3's end and expects Q4 EPS of $0.01–$0.04, primarily due to a legacy liability settlement gain, according to the company.

Original reporting
Published Nov 13, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Allarity Therapeutics (ALLR) Expects Q4 EPS of $0.01–$0.04 — source image
Decision brief

The 30-second read

$ALLRBearishMed
01

Why it matters

The guidance provides the first forward EPS estimate for Q4, setting market expectations.

02

Market read

New guidance may influence Allarity's stock price ahead of the upcoming quarter.

03

What to watch

Potential upcoming clinical data on stenoparib could offset modest EPS guidance.

Relevance 6/10Novelty 7/10Timing: ahead of Q4 earnings release

Background

Allarity Therapeutics reported Q3 cash position and issued Q4 EPS guidance based on a liability settlement.

Company-level read

Ticker impact

$ALLRBearishMedium confidence
Context

Allarity Therapeutics provided Q4 EPS guidance of $0.01–$0.04, a new forward-looking figure not previously disclosed.

Expected impact

likely modest downside as investors price in low EPS guidance

Evidence & confidence

The EPS range is low for a biotech and is driven by a one‑time liability settlement, offering limited upside.

Market effects

May temper sentiment toward early‑stage biotech earnings guidance.

Limited to US biotech investors.

Low, confined to Allarity shareholders.

Counterpoint

The liability settlement could be a catalyst if cash improves balance sheet, offering upside.

Key entities

  • Allarity Therapeutics

    Early‑stage clinical biotech issuing Q4 EPS guidance.

Related articles

$ALLRMedAI 8/10

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development - Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SP

$ALLRMed

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company

$ALLRMed

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when